NCT07272512 2025-12-19
ZSPAC-17
Shanghai Zhongshan Hospital
Phase 4 Recruiting
Clinical Trials
11 trialsNCT05077384 2025-09-16
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Phase 1/2 Completed
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT05989425 2023-08-14
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT05747729 2023-02-28
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02267967 2018-11-13
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Hutchmed
Phase 1 Completed